ARVO 2018: World’s Largest Show and Tell for Innovations in Eye Research

In addition to funding sight-saving research, we at FFB work hard to tell the scientific world about it. That’s because knowledge sharing and collaboration are critical to accelerating the advancement of promising therapies. Progress in developing treatments and cures isn’t made in a vacuum. The best opportunity for us to showcase FFB-funded research is at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), which is being held April 29 – May 3 this year in Honolulu. More than 11,000 eye researchers from around the world — including five intrepid members from FFB’s science team — will gather to participate in what is essentially a massive “show and tell” of the latest scientific advancements. This year at ARVO, FFB will have its own, impressive show and tell, highlighting nearly 100 posters and presentations on a variety of topics including:
  • MyRetinaTracker.org (our global patient registry),
  • FFB patient genetic testing program,
  • FFB ProgStar natural history study for Stargardt disease,
  • and dozens of FFB-funded research efforts for treatments and cures.
In addition, we’ll be hosting our 5th Retinal Innovation Summit, which convenes more than 200 researchers and industry leaders for 37 presentations on the latest developments in clinical trials and translational research for inherited retinal diseases. This pre-ARVO, one-day summit is co-hosted by Casey Eye Institute at Oregon Health & Science University, and sponsored by: Spark Therapeutics, AGTC, REGENXBIO and NightStar Therapeutics. Other examples of FFB-related sessions at ARVO include: How Foundations Can Enhance Clinical Trial Enrollment and Advance Patients as Partners Saturday, April 28, 3:45-4:00 p.m. HST, Room 316A Stephen Rose, PhD, FFB’s chief research officer will discuss how FFB has engaged patients to boost clinical trial enrollment, and opportunities to educate patients on how trials for specific treatments benefit the entire community of people with retinal diseases. Proctor Award: From Observations in the Retina Clinic to Insights into Pathophysiology Sunday, April 29, 10:45-11:30 a.m. HST, Ballrooms BC Sam Jacobson, MD, PhD, and Artur Cideciyan, PhD, FFB-funded researchers at the Scheie Eye Institute, University of Pennsylvania, are world leaders in clinical research for inherited retinal diseases. Among their many groundbreaking efforts, they played a key role in advancing RPE65 gene therapy into and through human studies. In addition to receiving the prestigious Proctor Award, they will deliver what is sure to be an insightful lecture on clinical diagnosis and the new era of vision-saving therapeutics. Optogenetics for Vision Restoration — Translation Sunday, April 29, 3:37-3:54 p.m. HST, Room 314 Optogenetics is an innovative approach for restoring vision to people who are completely blind from diseases like retinitis pigmentosa, regardless of the gene causing their vision loss. Deniz Dalkara, PhD, at the Institut de la Vision in Paris, will present FFB-funded research to move this approach into a clinical trial sponsored by GenSight. Genetic Testing Adds Research and Clinical Value to a Retinal Degeneration Registry Wednesday, May 2, 12:45-1:00 p.m. HST, Room 316C (paper session 4472) Kari Branham, genetic counselor at the University of Michigan’s Kellogg Eye Institute, will discuss how FFB’s genetic testing program and global patient registry (www.MyRetinaTracker.org) are boosting retinal-disease research and patient access to clinical trials and studies. Stay tuned to Eye on the Cure for updates from Honolulu on some of the outstanding research underway to save and restore vision. ALOHA for now!    

https://www.lvcenter4sight.com/arvo-2018-worlds-largest-show-and-tell-for-innovations-in-eye-research/

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more